PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
PharmaCyte Biotech, Inc.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$0.34+0.00 (+0.53%)
Close on Oct 19, 2026
- Market cap
- $3.67M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.6273 (−64.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
PharmaCyte Biotech, Inc. reported revenue of $0 for the twelve months to Apr 30, 2026.
Revenue
$0
TTM Q4 2026
Operating income
-$6.85M
TTM Q4 2026
EPS, diluted
-$2.77
TTM Q4 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $3.67M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$19.42M
- EPS, diluted
- -$2.77
- Book value per share
- $2.56
- Diluted shares
- 11M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
$0
Gross profit
–
Operating income
-$6.85M
Net income
-$19.42M-163.4% YoY
EPS, diluted
-$2.77-186.8% YoY
Reported period